FDA Clears Next-Gen Hybrid System for Intravascular Imaging

Why It Matters

Hybrid IVUS‑OCT imaging can reduce procedure time and improve decision‑making in complex coronary interventions, giving hospitals a competitive edge in delivering image‑guided care. The approval also positions Conavi to capture a growing market for integrated cath‑lab technologies.

Key Takeaways

• FDA clears Conavi's next-gen IVUS-OCT hybrid system
• System combines ultrasound and OCT imaging in one pullback
• Enables simultaneous plaque, vessel size, and stent assessment
• Expected U.S. market launch in H2 2026 after recall resolution

Pulse Analysis

Intravascular imaging has become a cornerstone of modern interventional cardiology, with IVUS and OCT each offering distinct insights into coronary pathology. IVUS excels at depth penetration, revealing plaque burden and vessel remodeling, while OCT provides high‑resolution cross‑sectional images of lumen and stent struts. Historically, clinicians have had to choose one modality or perform sequential scans, adding time, cost, and logistical complexity to procedures. The market has responded with demand for integrated solutions that can deliver both data sets without sacrificing workflow efficiency.

Conavi Medical’s newly cleared hybrid system merges IVUS and OCT into a single catheter and console, enabling a concurrent pullback that captures complementary data in real time. This dual‑modality approach allows operators to assess plaque composition, vessel dimensions, and post‑stent expansion simultaneously, potentially shortening procedure duration and reducing contrast usage. Early adopters, such as interventional cardiologists at New York‑Presbyterian, anticipate that the technology will enhance procedural precision, especially in complex lesions where both depth and surface detail are critical. By eliminating the need for separate catheters and imaging runs, cath labs can also reclaim valuable space and streamline inventory management.

From a business perspective, the clearance positions Conavi to tap into a $1.5 billion global intravascular imaging market that is projected to grow at a CAGR of over 7% through 2030. The limited release slated for the second half of 2026 will allow the company to gather real‑world performance data while scaling manufacturing capacity after a recent catheter recall. Competitors are racing to develop similar hybrid platforms, but Conavi’s early market entry and established relationships with clinical investigators could secure a first‑mover advantage. Successful commercialization could translate into significant revenue streams and bolster shareholder confidence as hospitals increasingly prioritize integrated, image‑guided solutions.